<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352701</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-LDS-ILA01</org_study_id>
    <nct_id>NCT02352701</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori</brief_title>
  <official_title>Efficacy and Safety of Basic Triple Therapy Including Ilaprazole, Levofloxacin on the First Line Eradication Treatment of H.Pylori</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Il-Yang Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Il-Yang Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared efficacy and safety of basic triple therapy including Ilaprazole 10mg,&#xD;
      Levofloxacin 500mg and Amoxicillin 1000mg BID for 10 days on the first line eradication&#xD;
      treatment of H.pylori&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compared efficacy and safety of basic triple therapy including Noltec(Ilaprazole)&#xD;
      10mg, Cravit(Levofloxacin) 500mg and Chongkundang Amoxicillin Cap(Amoxicillin) 1000mg BID on&#xD;
      the first line eradication treatment of H.pylori.&#xD;
&#xD;
      Participants are defined as persons who have endoscopically confirmed on gastric or duodenal&#xD;
      ulcer(including scar stage) and gastritis confirmed to be H.pylori positive patients in the&#xD;
      biopsy and UBT test. For 10 days, Participants treated as basic triple therapy including&#xD;
      Noltec(Ilaprazole) 10mg, Cravit(Levofloxacin) 500mg and Chongkundang Amoxicillin&#xD;
      Cap(Amoxicillin) 1000mg BID. After treatment, The healing rate was evaluated in the UBT test&#xD;
      and Biopsy at 49±5days from the first day dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The eradication rate of H.pylori at Day 49±5 as assessed by UBT test and Biopsy</measure>
    <time_frame>Day 49±5</time_frame>
    <description>The eradication rate of H.pylori after 10 days treatment is defined as those participants who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.&#xD;
The treatment : Noltec(Ilaprazole) 10mg+Chongkundang Amoxicillin(Amoxicillin) 1000mg+Cravit(Levofloxacin) 500mg was administered twice a day for 10days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of Noltec(Ilaprazole) 10mg BID treatment at Day 49±5. Record the number of patients with adverse Events</measure>
    <time_frame>Day 49±5</time_frame>
    <description>Record the number of patients with adverse Events. Also Record the symptoms, date, duration, and intensity of Adverse events such.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The healing rate of gastritis and ulcers at Day 49±5 as assessed by endoscopy confirmed to be active stage, healing stage and scarring stage.</measure>
    <time_frame>Day 49±5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of patients with Clarithromycin resistance as assessed by biopsy after treatment.</measure>
    <time_frame>Day 49±5</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">320</enrollment>
  <condition>Helicobacter Infections</condition>
  <arm_group>
    <arm_group_label>Noltec®,ChongkundangAmoxicillin®,Cravit®</arm_group_label>
    <description>Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noltec tab. 10mg</intervention_name>
    <description>Ilaprazole 10mg BID dosage form : delayed release tablet</description>
    <arm_group_label>Noltec®,ChongkundangAmoxicillin®,Cravit®</arm_group_label>
    <other_name>Ilaprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chongkundang Amoxicillin Cap. 500mg</intervention_name>
    <description>Amoxicillin 1000mg, BID dosage form : capsule</description>
    <arm_group_label>Noltec®,ChongkundangAmoxicillin®,Cravit®</arm_group_label>
    <other_name>Amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cravit Tab. 500mg</intervention_name>
    <description>Levofloxacin 500mg, BID dosage form : film coated tablet</description>
    <arm_group_label>Noltec®,ChongkundangAmoxicillin®,Cravit®</arm_group_label>
    <other_name>Levofloxacin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who visited the hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar)&#xD;
             or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.&#xD;
&#xD;
          -  Subject who fully understands conditions of clinical trial.&#xD;
&#xD;
          -  Subject who agrees to participate and spontaneously sign the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any component of ilaprazole, Amoxicillin and Levofloxacin&#xD;
&#xD;
          -  Subjects who are taking contraindicated medications for experimental and concomitant&#xD;
             drug.&#xD;
&#xD;
          -  Patients with abnormal levels in the laboratory tests&#xD;
&#xD;
               -  Total Bilirubin, Creatinine&gt; 1.5 times upper limit of normal&#xD;
&#xD;
               -  AST, ALT, Alkaline phosphatase, BUN&gt; 2 times upper limit of normal&#xD;
&#xD;
          -  Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of&#xD;
             the study.&#xD;
&#xD;
          -  Pregnant and/or lactating women&#xD;
&#xD;
          -  Reproductive aged women not using contraception&#xD;
&#xD;
          -  Uncontrolled diabetics&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Uncontrolled liver dysfunction&#xD;
&#xD;
          -  Alcoholics&#xD;
&#xD;
          -  Subjects with a history of digestive malignancy within 5 years&#xD;
&#xD;
          -  Subjects with a history of gastrectomy or esophagectomy&#xD;
&#xD;
          -  Subjects with hereditary diseases such as Galactose intolerance, Lapp lactose&#xD;
             deficiency, glucose-galactose malabsorption.&#xD;
&#xD;
          -  Subjects participating in a clinical trial before another trial wihin 30 days&#xD;
&#xD;
          -  Inconsistence judged subject by researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongsoo Lee, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic Univ. of Korea, Daejeon St.Mary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Daejeon St.Mary Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>ilaprazole</keyword>
  <keyword>eradication</keyword>
  <keyword>triple therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

